Show Notes
This week on The HighWire, Del Bigtree tackles the MAHA moment head-on, starting with rising backlash over the Trump Administration’s recent action on glyphosate and concerns about expedited production tied to Roundup.
Del is joined by Vani Hari (Food Babe) to discuss what’s happening right now in food policy and reform—and what it means for families.
Plus, Jefferey Jaxen takes us deeper into the Epstein files, focusing on what’s coming to light around medical/science publishing and influence.
And in a must-see in-studio interview, Del sits down with Dr. Michael Nehls on lithium—asking whether we’ve been missing (or denying) a truly essential element.
Guests: Vani Hari, Dr. Michael Nehls
Become a supporter of this podcast: https://www.spreaker.com/podcast/the-highwire-with-del-bigtree--3620606/support.
More from The Highwire with Del Bigtree
In a historic move in Washington, NIH has opened a new vaccine injury clinic, announced by Secretary Kennedy alongside leaders from NIH, CDC and CMS. For thousands of parents navigating their child’s regression after vaccination, could this clinic finally give them a place to be heard and a path to care?
A mysterious death inside a Russian plague research facility is raising questions far beyond the lab. With nearly 200 people reportedly placed under observation and international health agencies now watching closely, Jefferey Jaxen investigates what happened and why the story is drawing unsettling comparisons to the early days of COVID.
The COVID hospital protocols roundtable put grieving families, doctors, and lawmakers in the same room, asking a question the country has spent years avoiding: What really happened after patients entered the hospital?
Epidemiologist Nicolas Hulscher joins Del after testifying before the Michigan House using the Henry Ford vaccinated versus unvaccinated data featured in “An Inconvenient Study,” and why he says findings like these belong before lawmakers, not behind closed doors.
As millions turn to Ozempic to lose weight fast, and concerns are mounting over improper use, reports of blindness, life-threatening side effects, and billions in lawsuits are piling up. We look at the risks, the rush to prescribe, and what may be getting missed.